Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) has announced that its President and CEO, Todd C. Brady, M.D., Ph.D., will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:30 p.m. ET. A live webcast of the event will be available on the company's investor relations page and archived for 90 days afterward. Aldeyra focuses on developing treatments for immune-mediated diseases, with key products in clinical trials, including reproxalap for dry eye disease and allergic conjunctivitis.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 4:30 p.m. ET.

A live webcast of the fireside chat will be available on the investor relations page of the company’s corporate website at https://ir.aldeyra.com. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead product candidates, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005193/en/

FAQ

When is Aldeyra Therapeutics participating in the Jefferies Virtual Healthcare Conference?

Aldeyra Therapeutics will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:30 p.m. ET.

Who is representing Aldeyra Therapeutics at the conference?

Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra Therapeutics, will represent the company.

Where can I watch the Aldeyra Therapeutics fireside chat?

The fireside chat will be available via a live webcast on the investor relations page of Aldeyra's website.

How long will the Aldeyra Therapeutics conference webcast be available?

The webcast will remain archived on Aldeyra's website for 90 days after the event.

What is the focus of Aldeyra Therapeutics?

Aldeyra Therapeutics is focused on developing novel therapies for immune-mediated diseases, with key products in clinical trials.